Ongoing Cannabis Use Beyond First Trimester Linked to Depression Later in Pregnancy

Among 8,424 pregnant women in the nuMoM2b study, any cannabis exposure was not significantly associated with later depressive symptoms (aOR 1.3, 95% CI 0.97-1.6). However, ongoing exposure beyond the first trimester was significantly associated with depressive symptoms at 22-29 weeks (aOR 1.6, 95% CI 1.2-2.2). Higher urine THC metabolite levels correlated with greater odds of depression.

Secondary analysis of the nuMoM2b prospective cohort study (2010-2013) across eight academic centers. Cannabis exposure was verified by urine immunoassay for THC-COOH with LC-MS/MS confirmation at three timepoints. Depression was measured using the Edinburgh Postnatal Depression Scale (EPDS > 10). Multivariable logistic regression adjusted for confounders.

This is one of the largest studies to use objective biomarker-confirmed cannabis exposure (urine testing rather than self-report) to examine the timing and dose relationship between prenatal cannabis use and depression. The finding that timing matters, with ongoing use being the key risk factor rather than any use, adds important nuance.

The distinction between any exposure and ongoing exposure is clinically meaningful. Women who stopped cannabis use after the first trimester did not show elevated depression risk, while those who continued did. However, the study design cannot determine whether cannabis caused depression or whether worsening depression drove continued use.

Observational design cannot establish causation. Direction of association is unclear: depression may drive continued cannabis use rather than the reverse. Study enrolled participants 2010-2013, before more potent products became widespread. THC-COOH detection reflects recent use but does not capture frequency precisely.